8-K 1 d8k.htm CURRENT REPORT Current Report

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 16, 2003

 

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

(Exact name of Registrant as specified in its charter)

 

North Carolina   0-27570   56-1640186

(State or other jurisdiction of

incorporation)

  

(Commission

file Number)

  

(IRS Employer

ID Number)

 

3151 South 17th Street, Wilmington, North Carolina 28412

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code 919-251-0081

 

NA

(Former name or former address, if changed since last report)

 

 

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

 

(c) Exhibits

 

Exhibit No.
   

Description

99.1

    Press release dated July 16, 2003 of Pharmaceutical Product Development, Inc. (the “Company”), announcing its operating and financial results for the quarter ended June 30, 2003.

 

Item 9. Regulation FD Disclosure.

 

On July 16, 2003, the Company issued a press release announcing its operating and financial results for the quarter ended June 30, 2003. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

 

The information furnished in this Item 9 (which is being furnished under Item 12) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific release in such a filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Date: July 16, 2003     

   

Pharmaceutical Product Development, Inc.

 

 

By: /s/ Linda Baddour                

Name: Linda Baddour

Title: Chief Financial Officer